The Pharma Letter Podcast — Episode 6 — Patient empowerment and multiple sclerosis

Simon Wentworth

1 November 2021

janssen_podcast

More on this story...

Multiple sclerosis treatment fails to impress in mid-stage trial

21 March 2022

F-star Therapeutics bags $1.5 billion deal with Janssen

20 October 2021

Janssen receives MHRA authorization for Ponvory in RMS

11 August 2021

Mestag teams up with Janssen in inflammatory disease

18 May 2021

Companies featured in this story

More ones to watch >

Today's issue

Alloy and Takeda team up on CAR-T cell platform

Alloy and Takeda team up on CAR-T cell platform

21 November 2024

Eisai announces launch of Rozebalamin and Tasfygo

21 November 2024

Merck: a relentless pursuit of the best outcomes for the entire MS community

21 November 2024

Cidara to raise up to $105 million in private placement

21 November 2024

Novartis upgrades mid-term guidance; buys Kate Thera

21 November 2024

FDA approves Jazz’s Ziihera for HER2+ biliary tract cancer

21 November 2024

Lilly and Laekna team up on novel obesity drugs

21 November 2024

Company Spotlight

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.

More Features in Pharmaceutical

Eisai announces launch of Rozebalamin and Tasfygo

21 November 2024

Merck: a relentless pursuit of the best outcomes for the entire MS community

21 November 2024

Novartis upgrades mid-term guidance; buys Kate Thera

21 November 2024

Sage scraps dalzanemdor after disappointing trial results

21 November 2024

Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze